Lombard Odier Asset Management (Switzerland)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-133,656
| Closed | -$13.5M | – | 302 |
|
|
2023
Q1 | $13.5M | Sell |
133,656
-3,794
| -3% | -$384K | 1.18% | 28 |
|
|
2022
Q4 | $16.4M | Sell |
137,450
-61,642
| -31% | -$7.36M | 1.31% | 26 |
|
|
2022
Q3 | $21.1M | Sell |
199,092
-15,838
| -7% | -$1.68M | 1.79% | 10 |
|
|
2022
Q2 | $21M | Buy |
214,930
+24,362
| +13% | +$2.37M | 1.77% | 12 |
|
|
2022
Q1 | $17.9M | Sell |
190,568
-72,097
| -27% | -$6.76M | 1.4% | 33 |
|
|
2021
Q4 | $22.4M | Buy |
262,665
+22,682
| +9% | +$1.93M | 1.43% | 28 |
|
|
2021
Q3 | $23M | Buy |
239,983
+23,192
| +11% | +$2.22M | 1.43% | 32 |
|
|
2021
Q2 | $21.1M | Buy |
216,791
+66,927
| +45% | +$6.51M | 1.07% | 40 |
|
|
2021
Q1 | $14.6M | Buy |
+149,864
| New | +$14.6M | 0.97% | 42 |
|